Most cited papers from MedVadis Research

MedVadis Research

What are the most cited papers from MedVadis Research?

The most cited paper from MedVadis Research is "Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study" (MARCELO EDUARDO BIGAL, Lars IH Edvinsson, Alan M. Rapoport et al., 2015), with 264 citations. Next come "Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine" (69) and "Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine" (47).

Published TypeFieldAccess

Showing 19 of 19 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study MARCELO EDUARDO BIGAL, Lars IH Edvinsson, Alan M. Rapoport et al. · The Lancet Neurology	2 Oct 2015	264
2	Randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the safety and efficacy of ADAM zolmitriptan for the acute treatment of migraine Egilius L.H. Spierings, Jan Lewis Brandes, David Kudrow et al. · Cephalalgia Open access	12 Oct 2017	69
3	Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine Paul K Winner, Egilius L.H. Spierings, Paul P. Yeung et al. · Headache The Journal of Head and Face Pain	Nov 2019	47
4	A Phase I Study of the Safety of the Nutritional Supplement, Active Hexose Correlated Compound, AHCC, in Healthy Volunteers Egilius L.H. Spierings, Hajime Fujii, Buxiang Sun et al. · Journal of Nutritional Science and Vitaminology Open access	2007	43
5	Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine‐preventive medications in the phase 3b FOCUS study Egilius L.H. Spierings, Xiaoping Ning, Verena Ramirez Campos et al. · Headache The Journal of Head and Face Pain Open access	10 Aug 2021	30
6	Two-Minute Skin Anesthesia Through Ultrasound Pretreatment and Iontophoretic Delivery of a Topical Anesthetic: A Feasibility Study Egilius L.H. Spierings, Julie A. Brevard, Nathaniel P. Katz · Pain Medicine	2008	29
7	A Phase 2 Study of Fremanezumab as a Treatment for Posttraumatic Headache in Adult Patients (1588) Egilius L.H. Spierings, Stephen David Silberstein, Umer Najib et al. · Neurology	13 Apr 2021	12
8	A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting Ability Robert Alexander, Karen Raudibaugh, Egilius L.H. Spierings et al. · Clinical Journal of Pain	20 Oct 2020	8
9	A multicenter, prospective, single‐arm study of 60‐day peripheral nerve stimulation of the occipital nerves for the treatment of headache Genaro G. Gutierrez, Zachary L. McCormick, Mitchell Engle et al. · Headache The Journal of Head and Face Pain Open access	20 May 2025	7
10	Effectiveness and Safety of a New Zolmitriptan Rapid Absorption Microneedle Array (M207) for the Acute Treatment of Migraine (The ZOTRIP Study) (P4.125) Egilius L.H. Spierings, Donald J. Kellerman, Peter Christian Schmidt · Neurology	10 Apr 2018	3
11	Drugs in Development for Opioid-Induced Constipation Shannon J. Kelly, Egilius L.H., Dustin Tr · InTech eBooks Book chapterOpen access	7 Mar 2012	3
12	The Efficacy Of Continuous Non-Inhaled Intranasal Carbon Dioxide (CO2) In The Abortive Treatment Of Migraine: Results From Three Randomized, Double-Blinded, Placebo-Controlled Trials Egilius L.H. Spierings Open access	27 Aug 2024	2
13	A novel device for conservation of supplemental oxygen: A randomized, crossover study of the efficiency and non-inferiority of the OXFO System Kelly M Wawrzyniak, Giles Hooker, Susana Cristina Osorno Upegui et al. · Journal of Global Health Reports Open access	15 Oct 2024	1
14	Repeat Infusions of Eptinezumab Associated With Greater Migraine Reductions and Longer Migraine-Free Intervals: Results From the Phase 3 PROMISE-1 Trial (P4.108) Egilius L.H. Spierings, Timothy R. Smith, Roger K. Cady et al. · Neurology	10 Apr 2018	1
15	Onset of Action of a Zolmitriptan Microneedle System (M207, Qtrypta™) for Migraine: Comparison with Recent Early Time to Onset Recommendations, Pain Relief Results and Placebo Response (1977) Deborah Isa Friedman, Egilius L.H. Spierings, Jean Engels et al. · Neurology	13 Apr 2021	1
16	ID# 1905691 Durable Improvements in Headache Pain After 60-Day PNS: Six-Month Outcomes of a Prospective Single-Arm Study Genaro G. Gutierrez, Zachary L. McCormick, Mitchell Engle et al. · Neuromodulation Technology at the Neural Interface Open access	23 Sep 2025	0
17	Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine (P4.101) Ernesto Aycardi, Paul P. Yeung, Tricia Blankenbiller et al. · Neurology	10 Apr 2018	0
18	Interim Analysis of STS101 Nasal Safety Data From the Phase 3 Open-Label ASCEND Migraine Study (P13-12.006) Egilius L.H. Spierings, Detlef Albrecht, Alan M. Rapoport · Neurology	25 Apr 2023	0
19	Efficacy of Fremanezumab in Patients With Chronic Migraine Who Had Prior Use of Topiramate or OnabotulinumtoxinA (P4.104) Paul P. Yeung, Egilius L.H. Spierings, Tricia Blankenbiller et al. · Neurology	10 Apr 2018	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.